BC Week In Review | Feb 8, 2010
Company News

Argenta Discovery, Galapagos deal

Galapagos acquired Argenta's contract research business for €16.5 million ($22.9 million) in cash. Galapagos said the deal will expand its existing drug discovery services. Argenta reported 2009 revenue of €14 million ($19.4 million). The contract...
BC Extra | Feb 3, 2010
Company News

Galapagos acquires Argenta service business

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) acquired the contract research business of Argenta Discovery Ltd. (Harlow, U.K.) for EUR 16.5 million ($22.9 million) in cash. Galapagos said the acquisition will expand its existing drug discovery services. Argenta...
BC Week In Review | Sep 21, 2009
Clinical News

ADC4022: Phase II data

Data from 91 patients in a double-blind, U.K. and Polish Phase II trial showed that ADC4022 given in combination with inhaled budesonide significantly improved lung function as measured by difference between treatment groups in forced...
BC Extra | Sep 16, 2009
Clinical News

Argenta reports Phase II COPD data

In a Phase II trial in 91 patients with chronic obstructive pulmonary disease (COPD), Argenta Discovery Ltd. (Harlow, U.K.) said its ADC4022 plus inhaled budesonide significantly improved lung function vs. placebo plus budesonide. Data were...
BC Week In Review | Mar 3, 2008
Clinical News

ADC4022: Phase II started

Argenta began a double-blind, placebo-controlled, U.K. and Polish Phase II trial of ADC4022 plus an inhaled corticosteroid in 90 patients for 4 weeks. Argenta Discovery Ltd. , Harlow, U.K.   Product: ADC4022   Business: Pulmonary  ...
BC Innovations | Feb 14, 2008
Targets & Mechanisms

eRASing asthma

The mechanistic rationale for hypertension drugs that block the renin-angiotensin system in the circulation is clear: inhibit the process by which vasoconstriction occurs and blood pressure will go down. Cornell University researchers now suggest that...
BC Week In Review | Nov 13, 2006
Clinical News

ADC4022: Phase I started

Argenta began a U.K. Phase I trial in 36 healthy volunteers to evaluate the safety and pharmacokinetics of inhaled ADC4022 given alone and in combination with marketed inhaled corticosteroids. The first stage of the trial...
BC Week In Review | Nov 13, 2006
Clinical News

ADC4022: Phase I started

Argenta began a U.K. Phase I trial in 36 healthy volunteers to evaluate the safety and pharmacokinetics of inhaled ADC4022 given alone and in combination with marketed inhaled corticosteroids. The first stage of the trial...
Items per page:
1 - 8 of 8